Intracranial Bleeding as a Major Problem Among Neonates With Disseminated Intravascular Coagulation After the Introduction of Recombinant Thrombomodulin

J Pediatr Hematol Oncol. 2022 Apr 1;44(3):e807-e811. doi: 10.1097/MPH.0000000000002441.

Abstract

A standard treatment for disseminated intravascular coagulation in neonates has not yet been established. We analyzed the outcomes of 23 neonates who developed disseminated intravascular coagulation due to infection or asphyxia between 2004 and 2017. The overall survival rate was 95.7% on day 28 after anticoagulant therapy. In contrast, the bleeding-free survival rate was 69.6% (95% confidence interval, 53.1%-91.2%). Of the 6 neonates with intracranial bleeding, 2 developed neurological sequelae. The current study showed that intracranial bleeding remained a major problem in the early 2000s, despite the introduction of a new anticoagulant drug, recombinant thrombomodulin, at our institution since 2009.

MeSH terms

  • Anticoagulants / therapeutic use
  • Disseminated Intravascular Coagulation* / drug therapy
  • Disseminated Intravascular Coagulation* / etiology
  • Hemorrhage / drug therapy
  • Humans
  • Infant, Newborn
  • Intracranial Hemorrhages / chemically induced
  • Intracranial Hemorrhages / drug therapy
  • Recombinant Proteins / adverse effects
  • Thrombomodulin* / therapeutic use

Substances

  • Anticoagulants
  • Recombinant Proteins
  • Thrombomodulin